Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)
- Posted
- June 29, 2023
- Closed
- November 18, 2024
- Cost sharing
- No
- Instrument
- Grant
- Assistance listing
- 93.242
- Category
- Health
- Archives
- December 18, 2024
Program funding history
Awards made under Assistance Listing 93.242 across FY2025–FY2027, from public federal spending records.
- FY2025 obligated
- $1.8B
- FY2026 obligated
- $1.8B
- FY2027 (to date) obligated
- $0
- Awards in window
- 6,272
Top recipients: Yale Univ, University of Pittsburgh - of the Commonwealth System of Higher Education, Icahn School of Medicine at Mount Sinai, Trustees of the University of Pennsylvania, the, Washington University, the
Source: USAspending.gov · refreshed October 2026 · Program page: awards, recipients and the opportunities under this listing →
Synopsis
Although the majority living with schizophrenia and related disorders are over 35 years old, including those first diagnosed and those aging with the illness, the mechanisms underlying the generation and trajectory of the illness remain poorly understood. The purpose of this initiative is to advance translational research to better understand the emergence and trajectory of schizophrenia and related disorders in mid to late life, and to identity targets for future development of prevention and treatment efforts
Who can apply
- Small businesses
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Public housing authorities/Indian housing authorities
- City or township governments
- Private institutions of higher education
- For profit organizations other than small businesses
- Special district governments
- Native American tribal organizations (other than Federally recognized tribal governments)
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Native American tribal governments (Federally recognized)
- Public and State controlled institutions of higher education
- State governments
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- County governments
- Independent school districts
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
The official record
Grants.gov published the official terms and dates of this opportunity; this page keeps them as they were listed.
View on Grants.gov Full announcement
New to federal funding? How to read an announcement · Who can apply · How grants work
Tell me when this program posts again
This round has closed. One email the morning after this program is posted again under a new number (we watch for about two years), and one more about a week before that round closes (the next morning, if it is already closer than that). That is all this sends — it is not a newsletter signup.
Get grants like this every Tuesday — free
One email a week: the biggest new federal grants and what’s closing soon — the same list for everyone. Unsubscribe any time.
Similar grants
- Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
- Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
- Confirmatory Efficacy Clinical Trials of Non-Pharmacological and Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)
- First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based Interventions for Psychiatric Disorders (U01 Clinical Trial Required)
- Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)
- Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)
Same-day alerts, matched to you
The free digest is weekly — the same list for everyone. Members get every open federal grant scored to their organization — and an alert the day a real match posts: we read every new posting the day it opens. Free for 30 days, then $29/mo. Card required, cancel any time before day 31.
Not ready for a subscription? A one-time Fit Report — $29 — scores every open federal grant to your organization once, by email within one business day.
See pricing